AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29401242 — intervention group
Group type: EXPERIMENTAL
Intervention: Incompetence stereotypes
Number of subjects: 302
Study 28604516 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino Acid-based Formula (AAF) for 16 weeks
Number of subjects: 82
Study 28604516 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino Acid-based Formula (AAF)
Number of subjects: 82
Study 28604516 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino Acid-based Formula (AAF) and complementary foods
Number of subjects: 82
Study 26226283 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-contextual model-based intervention (12 weeks)
Number of subjects: 70
Study 26226283 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 70
Study 22631049 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 78
Study 22631049 — intervention group
Group type: COMPARATOR
Intervention: LOS/HCTZ
Number of subjects: 78
Study 21477416 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine IR (300 mg/d on days 9-12)
Number of subjects: 19
Study 21477416 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine XR (300 mg/d on days 5-8)
Number of subjects: 19
Study 21477416 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 19
Study 19500999 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of Pro‐Stat 64 supplementation
Number of subjects: 6
Study 19500999 — intervention group
Group type: EXPERIMENTAL
Intervention: Double dose of Pro‐Stat 64 supplementation
Number of subjects: 6
Study 19500999 — intervention group
Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 6
Study 16518128 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of methylphenidate
Number of subjects: 21
Study 15273006 — intervention group
Group type: EXPERIMENTAL
Intervention: Confrontation of racial bias from either target or nontarget group member
Number of subjects: 0
Study 15273006 — intervention group
Group type: EXPERIMENTAL
Intervention: Confrontation of gender bias from either target or nontarget group member
Number of subjects: 0
Study 15273006 — intervention group
Group type: EXPERIMENTAL
Intervention: Target confrontations (from Black or female)
Number of subjects: 0
Study 15273006 — intervention group
Group type: EXPERIMENTAL
Intervention: Nontarget confrontations (from White or male)
Number of subjects: 0
Study 11020910 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (100 mg mesulid, Pfizer)
Number of subjects: 32
Study 11020910 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (500 mg, Bayer)
Number of subjects: 32
Study 11020910 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 9025767 — intervention group
Group type: EXPERIMENTAL
Intervention: VMCP (vincristine, melphalan, cyclophosphamide, prednisolone)
Number of subjects: 94
Study 9025767 — intervention group
Group type: COMPARATOR
Intervention: MMPP (melphalan, ranimustine, procarbazine, prednisolone)
Number of subjects: 94
Study 9025767 — intervention group
Group type: EXPERIMENTAL
Intervention: VMCP to MMPP crossover
Number of subjects: 94
Study 9025767 — intervention group
Group type: EXPERIMENTAL
Intervention: MMPP to VMCP crossover
Number of subjects: 94
Study 9025767 — intervention group
Group type: EXPERIMENTAL
Intervention: VMCP
Number of subjects: 94
Study 9025767 — intervention group
Group type: COMPARATOR
Intervention: MMPP
Number of subjects: 94
Study 9025767 — intervention group
Group type: EXPERIMENTAL
Intervention: MP therapy (MPH/PSL combination)
Number of subjects: 94
Study 9025767 — intervention group
Group type: EXPERIMENTAL
Intervention: AT (alternating therapy with VMCP and MMPP)
Number of subjects: 94
Study 9025767 — intervention group
Group type: EXPERIMENTAL
Intervention: Plateau phase
Number of subjects: 94
Study 8331248 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 0.25% ophthalmic suspension (preserved with benzalkonium chloride)
Number of subjects: 27
Study 8331248 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol 0.25% ophthalmic suspension (unpreserved)
Number of subjects: 27
Study 3579256 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg every 6 h (five doses)
Number of subjects: 11
Study 3579256 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg every 12 h (three doses)
Number of subjects: 11
Study 28666964 — intervention group
Group type: EXPERIMENTAL
Intervention: Fournier® 200 mg capsule
Number of subjects: 3
Study 28666964 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipidil® 145 mg tablet
Number of subjects: 3
Study 28666964 — intervention group
Group type: EXPERIMENTAL
Intervention: HME 160 mg tablet
Number of subjects: 3
Study 28666964 — intervention group
Group type: COMPARATOR
Intervention: In vivo pharmacokinetic profiles
Number of subjects: 3
Study 27629349 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracellular space contrast agents (ECSCAs)
Number of subjects: 60
Study 27629349 — intervention group
Group type: COMPARATOR
Intervention: Blood-pool contrast agent (BPCA)
Number of subjects: 60
Study 24429305 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment arm (ART within 12 weeks of initiating standard first-line anti-tuberculosis treatment)
Number of subjects: 23
Study 24429305 — intervention group
Group type: COMPARATOR
Intervention: Sequential treatment arm (ART after completing anti-tuberculosis treatment)
Number of subjects: 23
Study 22395586 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of essential oil of Melaleuca alternifolia and organically bound iodine (TTO-I)
Number of subjects: 53
Study 22395586 — intervention group
Group type: COMPARATOR
Intervention: Iodine alone
Number of subjects: 53
Study 22395586 — intervention group
Group type: COMPARATOR
Intervention: Essential oil of Melaleuca alternifolia (TTO)
Number of subjects: 53
Study 20690152 — intervention group
Group type: EXPERIMENTAL
Intervention: XIENCE V everolimus‐eluting stent (EES)
Number of subjects: 212
Study 18684548 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression to ventilation ratio 30:2
Number of subjects: 18
Study 18684548 — intervention group
Group type: COMPARATOR
Intervention: Compression to ventilation ratio 15:2
Number of subjects: 18
Study 15985728 — intervention group
Group type: EXPERIMENTAL
Intervention: Indigenous recombinant streptokinase (Shankinase, r-SK)
Number of subjects: 150
Study 15985728 — intervention group
Group type: COMPARATOR
Intervention: Natural streptokinase (Streptase, n-SK)
Number of subjects: 150
Study 12682335 — intervention group
Group type: EXPERIMENTAL
Intervention: MRS brain metabolite ratio N-acetylaspartate (NAA)/myo-inositol (mI) in subjects with small hippocampal volumes
Number of subjects: 60
Study 12682335 — intervention group
Group type: COMPARATOR
Intervention: MRS brain metabolite ratio N-acetylaspartate (NAA)/myo-inositol (mI) in other subjects
Number of subjects: 60
Study 10550740 — intervention group
Group type: EXPERIMENTAL
Intervention: sublingual‐swallow immunotherapy
Number of subjects: 30
Study 10550740 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study 8889480 — intervention group
Group type: EXPERIMENTAL
Intervention: H-wave therapy at 16 Hz
Number of subjects: 32
Study 8889480 — intervention group
Group type: EXPERIMENTAL
Intervention: H-wave therapy at 60 Hz
Number of subjects: 32
Study 8889480 — intervention group
Group type: EXPERIMENTAL
Intervention: H-wave therapy at 2 Hz
Number of subjects: 32
Study 8889480 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study 1792609 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 13
Study 1792609 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 13
Study 7215765 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol Hydrobromide
Number of subjects: 112
Study 30790569 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapan-S
Number of subjects: 419
Study 30790569 — intervention group
Group type: COMPARATOR
Intervention: Foley balloon
Number of subjects: 419
Study 27743214 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezon Master 700 with NO PAIN technology
Number of subjects: 100
Study 27743214 — intervention group
Group type: COMPARATOR
Intervention: Mini Piezon without NO PAIN technology
Number of subjects: 100
Study 25724644 — intervention group
Group type: EXPERIMENTAL
Intervention: Pradigastat (100 mg for 3 days followed by 40 mg for 7 days, 1 hour before meal)
Number of subjects: 25
Study 25724644 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen (1000 mg)
Number of subjects: 25
Study 24582486 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin (AUC 2 mg/mL per min) plus paclitaxel (60 mg/m(2)) every week for 18 weeks
Number of subjects: 810
Study 24582486 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin (AUC 6 mg/mL per min) plus paclitaxel (175 mg/m(2)) every 3 weeks for six cycles
Number of subjects: 810
Study 18596290 — intervention group
Group type: EXPERIMENTAL
Intervention: Language-focused curriculum (LFC)
Number of subjects: 14
Study 18596290 — intervention group
Group type: COMPARATOR
Intervention: Prevailing curriculum
Number of subjects: 14
Study 15507885 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral defibrotide (800 mg/die)
Number of subjects: 288
Study 15507885 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 288
Study 11331472 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem (1.0 g plus cilastatin intravenously 3 times a day)
Number of subjects: 90
Study 11331472 — intervention group
Group type: COMPARATOR
Intervention: Control group (delayed antibiotics)
Number of subjects: 90
Study 9425396 — intervention group
Group type: EXPERIMENTAL
Intervention: Human recombinant growth hormone (rhGH) replacement therapy at a dosage of 12.5 micrograms/kg/day (initial dosage during the first 4 weeks 6.25 micrograms/kg/day)
Number of subjects: 17
Study 8245105 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-acid-buffering prophylaxis therapy (6 patients)
Number of subjects: 19
Study 8245105 — intervention group
Group type: COMPARATOR
Intervention: Standard antacid or antacid/H2 histamine-blocking agent combination prophylaxis therapy (13 patients)
Number of subjects: 19
Study 8245105 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 19
Study 3681765 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline
Number of subjects: 34
Study 3681765 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 34
Study 11319676 — intervention group
Group type: EXPERIMENTAL
Intervention: Device (n = 32)
Number of subjects: 61
Study 11319676 — intervention group
Group type: COMPARATOR
Intervention: Walkman (n = 29)
Number of subjects: 61
Study 30882239 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 3584
Study 30882239 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3584
Study 30340777 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular coiling (EV)
Number of subjects: 351
Study 30340777 — intervention group
Group type: COMPARATOR
Intervention: Microsurgical clipping (MS)
Number of subjects: 351
Study 26491112 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (5 mg)
Number of subjects: 70
Study 26491112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 25362221 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene, 60 mg/d for 8 months
Number of subjects: 60
Study 25362221 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 months
Number of subjects: 60
Study 25362221 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene and Placebo
Number of subjects: 60
Study 22300538 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 127
Study 22300538 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 127
Study 20822213 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic numerical cognition
Number of subjects: 280
Study 20822213 — intervention group
Group type: EXPERIMENTAL
Intervention: Domain-general abilities
Number of subjects: 280
Study 20822213 — intervention group
Group type: EXPERIMENTAL
Intervention: Counting span
Number of subjects: 280
Study 20822213 — intervention group
Group type: EXPERIMENTAL
Intervention: Language, attentive behavior, nonverbal problem solving, and listening span
Number of subjects: 280
Study 17369678 — intervention group
Group type: EXPERIMENTAL
Intervention: Band ligation
Number of subjects: 32
Study 17369678 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection sclerotherapy
Number of subjects: 32
Study 17369678 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal age-matched controls)
Number of subjects: 32
Study 15621317 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral posture for flexion
Number of subjects: 39
Study 15621317 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral posture for extension
Number of subjects: 39
Study 15621317 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing angular deviation of the neck
Number of subjects: 39
Study 15621317 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of males and females
Number of subjects: 39
Study 15621317 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall flexion-extension ratio
Number of subjects: 39
Study 15621317 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral posture vs flexion and extension
Number of subjects: 39
Study 11979650 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical mupirocin (Bactroban) applied to nares and catheter exit site
Number of subjects: 2
Study 11979650 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2
Study 10023498 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 100 mg
Number of subjects: 0
Study 10023498 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 250 mg
Number of subjects: 0
Study 10023498 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 500 mg
Number of subjects: 0
Study 10023498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7751428 — intervention group
Group type: EXPERIMENTAL
Intervention: Local phentolamine (administered directly into a preconstricted hand vein)
Number of subjects: 0
Study 7751428 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic phentolamine (administered intravenously)
Number of subjects: 0
Study 7751428 — intervention group
Group type: COMPARATOR
Intervention: Control (vehicle solutions)
Number of subjects: 0
Study 2321541 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3.3 mg/kg)
Number of subjects: 34
Study 2321541 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 43755 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 40 mg
Number of subjects: 8
Study 43755 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 5 mg
Number of subjects: 8
Study 43755 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol 10 mg
Number of subjects: 8
Study 43755 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 8
Study 31338773 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06439535 plus paclitaxel and carboplatin
Number of subjects: 719
Study 31338773 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab-EU plus paclitaxel and carboplatin
Number of subjects: 719
Study 31338773 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06439535 and Bevacizumab-EU
Number of subjects: 719
Study 28475467 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-pressure condition
Number of subjects: 21
Study 28475467 — intervention group
Group type: EXPERIMENTAL
Intervention: Compliant-only analysis
Number of subjects: 21
Study 28475467 — intervention group
Group type: EXPERIMENTAL
Intervention: Intent-to-treat analysis
Number of subjects: 21
Study 28475467 — intervention group
Group type: COMPARATOR
Intervention: Forced-delay condition
Number of subjects: 21
Study 25204277 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 0
Study 25204277 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 23370902 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5-mg intravitreal ranibizumab
Number of subjects: 261
Study 23370902 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal saline
Number of subjects: 261
Study 21550313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime infusion plus paracetamol
Number of subjects: 723
Study 21550313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime infusion
Number of subjects: 723
Study 21550313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime bolus plus paracetamol
Number of subjects: 723
Study 21550313 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime bolus
Number of subjects: 723
Study 21550313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 723
Study 19189066 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose antithrombin (AT) without simultaneous heparin treatment
Number of subjects: 0
Study 19189066 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose antithrombin (AT) without simultaneous heparin treatment in risk group grade II patients
Number of subjects: 0
Study 19189066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17536000 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) at 0.06 mg/kg.d for 2 years (group I)
Number of subjects: 76
Study 17536000 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone (GH) for 12 months after 12 months of no treatment (group II)
Number of subjects: 76
Study 14990550 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 ml/kg of 0.9% NaCl infusion over 60 min
Number of subjects: 18
Study 14990550 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 degrees head-down position
Number of subjects: 18
Study 14990550 — intervention group
Group type: COMPARATOR
Intervention: 15 degrees feet-down position
Number of subjects: 18
Study 11810323 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine (150 mg)
Number of subjects: 135
Study 11810323 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (1 mg or 5 mg)
Number of subjects: 135
Study 11810323 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 5 mg morphine and 75 mg ropivacaine
Number of subjects: 135
Study 11810323 — intervention group
Group type: COMPARATOR
Intervention: Control group (isotonic saline)
Number of subjects: 135
Study 9732164 — intervention group
Group type: EXPERIMENTAL
Intervention: cetirizine 10 mg
Number of subjects: 18
Study 9732164 — intervention group
Group type: COMPARATOR
Intervention: ebastine 10 mg
Number of subjects: 18
Study 8054406 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisuride (up to 4.0 mg daily for 3 weeks)
Number of subjects: 0
Study 8054406 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2845239 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 12
Study 2845239 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 12
Study 29993216 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (10%)
Number of subjects: 60
Study 29993216 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 60
Study 26010873 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with CF
Number of subjects: 0
Study 26010873 — intervention group
Group type: COMPARATOR
Intervention: Peers with experience of CF
Number of subjects: 0
Study 26010873 — intervention group
Group type: COMPARATOR
Intervention: Peers without experience of CF
Number of subjects: 0
Study 26510448 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg twice daily for 24 weeks
Number of subjects: 66
Study 26510448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 26510448 — intervention group
Group type: COMPARATOR
Intervention: Metformin vs Placebo
Number of subjects: 66
Study 24027289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training coupled with parietal tRNS (transcranial random noise stimulation)
Number of subjects: 40
Study 24027289 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training without stimulation
Number of subjects: 40
Study 24027289 — intervention group
Group type: COMPARATOR
Intervention: Stimulation without cognitive training
Number of subjects: 40
Study 24027289 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training coupled to stimulation of a control site (motor areas)
Number of subjects: 40
Study 24027289 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training with parietal tRNS
Number of subjects: 40
Study 21606960 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavopiridol
Number of subjects: 116
Study 18340100 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial continuous insonation using a 1.8-MHz Doppler ultrasound (US) probe for 1 hour
Number of subjects: 37
Study 18340100 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ultrasound)
Number of subjects: 37
Study 16601292 — intervention group
Group type: EXPERIMENTAL
Intervention: Subsequent endocrine therapy after fulvestrant
Number of subjects: 54
Study 16594273 — intervention group
Group type: EXPERIMENTAL
Intervention: Control-enhanced condition (caring for a plant)
Number of subjects: 20
Study 16594273 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (comparison condition)
Number of subjects: 20
Study 11225738 — intervention group
Group type: COMPARATOR
Intervention: School-based mental health programs
Number of subjects: 47
Study 11225738 — intervention group
Group type: COMPARATOR
Intervention: Implementation features
Number of subjects: 47
Study 9322561 — intervention group
Group type: EXPERIMENTAL
Intervention: 4184 kJ meal
Number of subjects: 16
Study 9322561 — intervention group
Group type: EXPERIMENTAL
Intervention: 2092 kJ meal
Number of subjects: 16
Study 16350577 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone (T)
Number of subjects: 0
Study 16350577 — intervention group
Group type: COMPARATOR
Intervention: Dihydrotestosterone (DHT)
Number of subjects: 0
Study 16350577 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 3161487 — intervention group
Group type: EXPERIMENTAL
Intervention: tocainide HC1 900 mg/day
Number of subjects: 48
Study 3161487 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 48